Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

Tokyo, Japan, and Lugano, Switzerland March 28 (Korea Bizwire) - Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) and Helsinn Group (hereinafter “Helsinn”), announced today that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug “Arokaris® I.V. Infusion 235mg” (generic name: fosnetupitant chloride hydrochloride) for gastrointestinal symptoms (nausea and vomiting, [...]